Anzeige
Mehr »
Sonntag, 06.07.2025 - Börsentäglich über 12.000 News
Surfen Sie die heißeste Edelmetall-Welle des Jahrzehnts! Dieses TOP-Unternehmen zündet nächste Wachstumsstufe!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PNH3 | ISIN: US14843C1053 | Ticker-Symbol:
NASDAQ
03.07.25 | 18:31
20,255 US-Dollar
-0,22 % -0,045
1-Jahres-Chart
CASTLE BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
CASTLE BIOSCIENCES INC 5-Tage-Chart

Aktuelle News zur CASTLE BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
19.06.Castle Biosciences, Inc.: Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)188FRIENDSWOOD, Texas, June 19, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on...
► Artikel lesen
CASTLE BIOSCIENCES Aktie jetzt für 0€ handeln
17.06.Castle Biosciences stock steady as Canaccord reiterates buy rating2
17.06.SciBase has signed a Collaboration and License Agreement with Castle Biosciences to develop diagnostic tests within dermatology and intends to carry out a directed share issue of approximately MSEK 30256STOCKHOLM, June 17, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced it has signed...
► Artikel lesen
16.06.Castle Biosciences partners with SciBase for diagnostic tests1
16.06.Castle Biosciences partners with SciBase to develop atopic dermatitis test1
16.06.Castle Biosciences, Inc.: Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases91FRIENDSWOOD, Texas, June 16, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it...
► Artikel lesen
11.06.Castle Biosciences, Inc.: Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention1
29.05.Castle Biosciences, Inc.: New Data at ASCO 2025 Affirms DecisionDx-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes2
23.05.Castle Biosciences ändert Satzung, Aktionäre stimmen ab2
23.05.CASTLE BIOSCIENCES INC - 8-K, Current Report1
21.05.Scotiabank cuts Castle Biosciences target to $40, maintains rating5
09.05.Castle Biosciences bestätigt Wirksamkeit des UM-Tests1
09.05.Castle Biosciences confirms UM test's efficacy3
09.05.Castle Biosciences, Inc.: Real-World Study Confirms Long-Term Performance of DecisionDx-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM ...193FRIENDSWOOD, Texas, May 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data...
► Artikel lesen
07.05.Castle Biosciences, Inc.: Castle Biosciences Celebrates Skin Cancer Awareness Month1
06.05.Castle Biosciences projects $287-$297M revenue for 2025 amid strategic acquisitions and growth initiatives1
06.05.KeyBanc maintains Castle Biosciences stock with $36 target1
06.05.BTIG cuts Castle Biosciences stock target to $32, keeps Buy rating2
06.05.Castle Biosciences to Acquire Previse2
06.05.Castle Biosciences Q1 2025 slides: Strong revenue growth overshadowed by earnings miss1
Weiter >>
48 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1